Skip to main content

Day: August 25, 2020

Karolinska Development’s Board director Magnus Persson resigns from his position

STOCKHOLM, SWEDEN – 25 August, 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that Magnus Persson has decided to resign from his position as member of the company’s Board of directors.Magnus Persson has been a Board director of Karolinska Development since 2017. He is now leaving his post at his own request and with immediate effect, to focus on his role as founding partner in Eir Ventures, a recently started fund for investments in the life science sector.For further information, please contact:Björn Cochlovius, Board director, Karolinska Development ABTel: +49 151 17555444, e-mail: bjorn.cochlovius@karolinskadevelopment.comTO THE EDITORSAbout Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough...

Continue reading

Karolinska Developments styrelseledamot Magnus Persson lämnar sitt uppdrag

STOCKHOLM, SVERIGE 25 augusti 2020. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att Magnus Persson har beslutat sig för att lämna sitt uppdrag som styrelseledamot i bolaget.Magnus Persson har varit styrelseledamot i Karolinska Development sedan 2017. Han lämnar nu sitt uppdrag på egen begäran och med omedelbar verkan för att fokusera på sin roll som grundare och partner i Eir Ventures, en nystartad fond för investeringar i life science-sektorn.För ytterligare information, vänligen kontakta:  Björn Cochlovius, styrelseledamot, Karolinska Development ABTel: +49 151 17555444, e-mail: bjorn.cochlovius@karolinskadevelopment.comTILL REDAKTÖRERNAOm Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar på att identifiera medicinska...

Continue reading

Knee Replacement Market to Exhibit a CAGR of 4.3% to Reach USD 12.48 Billion by 2027; Launch of Zimmer’s Persona Partial Knee System to Augment Growth, states Fortune Business Insights™

Pune, Aug. 25, 2020 (GLOBE NEWSWIRE) — Global knee replacement market is expected to reach USD 12.48 billion by 2027, exhibiting a CAGR of 4.3% during the forecast period.The growing cases of arthritis among the general population can be a crucial factor augmenting the growth of the market, states Fortune Business Insights, in a report, titled “Knee Replacement Market Size, Share & Industry Analysis, By Procedure (Total Knee Arthroplasty, Partial Knee Arthroplasty, and Revision Arthroplasty) By Implant Type (Fixed Bearing, Mobile Bearing, and Others) End-user (Hospitals, Orthopedic Clinics, Ambulatory Surgical Centers, and Others) and Regional Forecast, 2020-2027” the market size stood at USD 9.45 billion in 2019.The coronavirus crisis has caused immense damage to the world’s economy. We understand that this health emergency...

Continue reading

Veterinary Drugs Market to Worth US$ 27,570 Mn Gaining Impetus from Government Support, says Fortune Business Insights

Pune, Aug. 25, 2020 (GLOBE NEWSWIRE) — The Global Veterinary Drugs Market will reach a valuation of US$ 27,570 Mn by 2025 from US$ 17,870.6 Mn in 2017, and exhibit a promising CAGR of 5.6% over the aforementioned forecast period.The parasiticides segment accounted for the highest share in 2017 with a market revenue of 32.2% and is likely to dominate the market in terms of product segmentation. This is because prevention of animals from insects and parasites is extremely important, in order to avoid its devastating impact on the animals and further on humans consuming products derived from such animals such as milk, eggs, and meat.Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/veterinary-drugs-market-100171Rise in Intake of Meat Consumption to Propel MarketThe rise...

Continue reading

Síminn hf. – Stöðugur rekstur á öðrum ársfjórðungi

Helstu niðurstöður úr rekstri á 2F 2020Á ársfjórðungnum var gjaldfærð 500 milljón króna stjórnvaldssekt vegna ákvörðunar Samkeppniseftirlitsins frá því í lok maí sem hefur neikvæð áhrif á afkomu fjórðungsins. Félagið hefur kært ákvörðunina til áfrýjunarnefndar samkeppnismála og mun niðurstaða væntanlega liggja fyrir síðar á þessu ári.Tekjur á öðrum ársfjórðungi (2F) 2020 námu 7.276 milljónum króna samanborið við 7.115 milljónir króna á sama tímabili 2019 og hækka því um 161 milljón krónur eða 2,3%.Rekstrarhagnaður fyrir afskriftir og fjármagnsliði EBITDA nam 1.938 milljónum króna á 2F 2020 samanborið við 2.602 milljónir króna á sama tímabili 2019 og lækkar því um 664 milljónir króna eða 25,5% frá sama tímabili í fyrra. EBITDA hlutfallið er 26,6% fyrir annan ársfjórðung 2020 en var 36,6% á sama tímabili 2019.Hagnaður á 2F 2020 nam 83 milljónum...

Continue reading

Síminn hf. – Continuous Operation in Q2

Financial highlights Q2 2020In the quarter Síminn was charged ISK 500 million due to the Competition Authority‘s decision from the end of May, which has a negative effect on the quarter‘s result. Síminn has appealed the ruling to the Competition Appeals Committee and the result is expected later this year.Síminn‘s revenue amounted to ISK 7,276 million in the second quarter (Q2) of 2020, compared to ISK 7,115 million in the same period 2019. An increase by ISK 161 million or 2.3%.EBITDA amounted to ISK 1,938 million in Q2 2020, compared to ISK 2,602 million in the same period of 2019, down by ISK 664 million or 25.5%. The EBITDA ratio was 26.6% in Q2 2020, compared to 36.6% in the same period of 2019.Profit in Q2 2020 amounted to ISK 83 million, compared to ISK 798 million in the same period of 2019.Cash generated by operation amounted...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.